Page 53 - Demo
P. 53
DESTINY-PanTumor01: ORR%u2022 Phase 2 global basket study%u2022 Patients with advanced solid tumors harboring prespecified HER2 mutations%u2022 Progressed on previous systemic therapy%u2022 Trastuzumab deruxtecan 5.4 mg/kg q3w%u2022 Primary endpoint: ORR by central reviewLi BT, et al. Lancet Oncol. 2024;25(6):707-719.
